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Abstract 
Anthracyclines are among the most widely used drugs in oncology, being part of the treatment 
regimen in most patients receiving systemic chemotherapy. This review provides a 
comprehensive summary of the sample preparation techniques and chromatographic methods 
that have been developed during the last two decades for the analysis of the 4 most 
administered anthracyclines, doxorubicin, epirubicin, daunorubicin and idarubicin in plasma, 
serum, saliva or urine, within the context of clinical and pharmacokinetic studies or for 
assessing occupational exposure. Following deproteinization, liquid-liquid extraction, solid 
phase extraction or a combination of these techniques, the vast majority of methods utilizes 
reversed-phase C18 stationary phases for liquid chromatographic separation, followed by 
fluorescence detection, or, more recently, tandem mass spectrometric detection. Some pros 
and cons of the different techniques are addressed, in addition to potential pitfalls that may be 
encountered in the analysis of this class of compounds. 
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1. Introduction 
 
In the early 1960s the first identified anthracyclines, daunorubicin (synonym: daunomycin) 
and doxorubicin (synonym: adriamycin), were isolated from pigment producing Streptomyces 
spp [1]. These anthracyclines, together with their semi-synthetic derivatives idarubicin and 
epirubicin (synonym: epiadriamycin), are by far the most frequently administered in clinical 
practice today. Doxorubicin has indications in the treatment of a wide variety of adult solid 
tumours (breast, ovarian, gastric cancer, …), as well as in the treatment of childhood and 
haematological malignancies. Epirubicin is primarily used in the treatment of adult solid 
tumours (especially breast cancer), whereas daunorubicin and idarubicin are primarily used 
for treating both adult and paediatric leukaemia. In fact, an anthracycline is part of the 
regimen for most patients receiving systemic chemotherapy at some time during treatment [2]. 
Chemically, all anthracyclines consist of an aglycone ring coupled to an amino sugar (Fig. 1). 
The aminosugar has basic properties (pKa about 7.5), while the two hydroquinone groups are 
acidic (pKa’s about 9.5 and 10) [3,4]. 
Idarubicin is the only anthracycline that can be administered both orally and intravenously. 
Bioavailability is about 30%, but varies widely between patients [5]. All other anthracyclines 
are only administered intravenously, predominantly as bolus injection [6]. 
After bolus administration, plasma anthracycline levels undergo a decay, which can generally 
be best fitted by a triexponential model, although also biexponential models -the intermediate 
phase not always being apparent- have been described [6-8]. Despite the fact that a 
considerable heterogeneity in the pharmacokinetic parameters of anthracyclines has been 
observed, both within and between studies, the plasma-concentration-time curve after short 
intravenous infusion can be roughly characterised by i) a rapid initial () distribution phase, 
lasting up to 1 hour, with half-lives in the range of minutes, ii) an intermediate () phase, with 
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half-lives in the range of a few hours, and iii) a much slower () terminal elimination phase, 
apparently established after 12 to 24 hours, with half-lives in the order of days [6,9]. 
Anthracyclines are bound to plasma proteins to an extent of about 70-85% [6,10]. When 
measured in various organs and in tumours, anthracycline concentrations always exceed 
plasma concentrations, reflecting the high distribution volume of these drugs [6]. 
The stereospecific reduction of anthracyclines by cytoplasmic aldo-keto reductases of the 
carbonyl function at C13 in the aglycone moiety yields pharmacologically active 13-S-dihydro 
metabolites, which are generally denoted by the suffix “-ol” (so doxorubicinol, epirubicinol, 
daunorubicinol and idarubicinol) (Fig. 1). Generally, daunorubicin and idarubicin are 
converted more extensively than doxorubicin and epirubicin. Inactive aglycones are formed 
by deglycosylation of the anthracyclines, and are generally denoted by the suffix “one”. Since 
doxorubicin and epirubicin only differ by their sugar-moiety, they have identical aglycone 
metabolites. Hydrolase-type activity yields aglycones that possess a hydroxyl function at 
position C7. The 7-deoxy aglycones are present in biological fluids in only some patients, 
transiently, and at very low concentrations [11]. Epirubicin is characterized by a unique 
metabolic pathway present only in humans: in contrast to other anthracyclines, the hydroxyl 
function at C4’ in the sugar moiety is positioned equatorially, opening the possibility of 
glucuronic acid conjugation [12]. Peak plasma concentrations of epirubicin and epirubicinol 
glucuronides are found 1 to 2 hours after administration of epirubicin, and their plasma 
concentrations generally exceed those of the parent drug. Glucuronides are devoid of any 
cytotoxic activity [6]. Formation of epirubicin and epirubicinol from their respective 
glucuronides by means of enterohepatic recycling has not been described. However, we found 
the pharmacokinetic profiles from epirubicin-treated patients to contain a slight increase 4h 
post-I.V. infusion, which may be indicative that enterohepatic recycling may exist [13]. 
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The relevance of the analytical determination of chemotherapeutics, and of anthracyclines in 
particular, lies in the fact that there is a marked inter-individual variation in the occurrence of 
unwanted toxicity. When aiming at maximizing therapeutic efficiency while reducing toxic 
side effects, validated analytical methods are needed to establish the pharmacokinetics of 
these compounds. Rather than considering a therapeutic interval, parameters taken into 
consideration include area under the plasma-concentration-time curve (AUC), plasma 
concentration 2h post-dose and/or terminal half-life [14]. 
More than a decade has past since the publication of the last comprehensive reviews covering 
determination of anthracyclines [15-17]. Given the new developments in the field -amongst 
which the use of tandem mass spectrometry- the aim of the current review is to bundle 
chromatographic strategies, new insights and developments for the detection of anthracyclines 
in biological matrices. First some aspects concerning the stability of anthracyclines in stock 
solutions and biological fluids will be discussed. Subsequently, the analytical aspects for 
clinical and pharmacokinetic studies, as well as for assessing occupational exposure will be 
reviewed. 
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2. Stability of anthracyclines 
 
2.1. Stock solutions  
Anthracyclines require great care in handling. Firstly, they adsorb to a variety of materials 
such as glass and polystyrene [3,18]. Polypropylene is recommended [19]. Secondly, 
anthracyclines are photolabile [20]. Stock solutions in alcohols are stable at -20 °C, but the 
stability reduces in aqueous solutions, especially with increasing pH, but also in an acidic 
environment [21,22]. 
 
2.2. Stability in biological fluids 
In order to avoid misinterpretations of the bioanalytical results certain precautions concerning 
the handling of biological samples are inevitable. First of all, blood cells need to be removed 
immediately after collection of a blood sample, since they rapidly concentrate anthracyclines, 
which then become a substrate for the cytoplasmic aldo-keto reductase enzymes [23]. 
Although no instability in serum has been reported, plasma is by far the most utilised matrix 
for anthracycline analysis [15]. Anthracyclines are reported to be stable in plasma when 
stored at -20 °C or lower. They have been recovered reproducibly after up to ten cycles of 
thawing and refreezing at -70 °C [24]. However, the choice of anticoagulant can be highly 
relevant. It has been demonstrated that heparin may directly interact with anthracyclines, 
interfering with their analysis, especially when starting from aqueous solutions or from 
plasma samples with high anthracycline concentrations. Therefore EDTA tubes are 
recommended [19,25,26]. Although data are scarce, no significant instability was reported in 
saliva and oral fluid. However, repeated freeze-thawing cycles have been noted to exhibit a 
detrimental effect [27]. 
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It has been recommended to acidify urine samples upon storage to prevent degradation [28]. 
However, it should be evaluated whether this does not lead to hydrolysis of epirubicin(ol) 
glucuronide. 
 
 
3. Determination for clinical and pharmacokinetic studies  
Doxorubicin, epirubicin, daunorubicin and idarubicin are by far the most frequently 
administered anthracyclines. In an attempt to overcome their toxicity or drug resistance, 
prodrugs and special pharmaceutical formulations have been developed. Since these changes 
often require a different analytical approach, the interested reader is referred to the individual 
methods regarding the analysis of peptide-conjugated [29-31] or polymer-bound [32] 
prodrugs and micellar [33], pegylated liposomal [33-35], liposomal [36,37] or embolizing 
[38-40] formulations. Here we present an overview of 35 original methods published since 
1990 for the determination of doxorubicin, epirubicin, daunorubicin, idarubicin and 
metabolites in biological fluids. The individual methods are summarized in Table 1. 
 
3.1. Analytes and concentrations of interest  
It is important to determine not only the main compounds, but also their respective 13-S-
dihydro metabolites, which are not only pharmacologically active, but also have been linked 
to anthracycline’s cardiotoxic side effects [14,41]. Aglycones and glucuronides (in the case of 
epirubicin) can be measured, but are not considered to be toxicologically relevant [6]. 
Nevertheless, great care should be taken that these metabolites do not interfere in the 
determination of the main compounds or their reduced metabolites. From the 35 publications 
included in this overview, 12 quantify only one main compound [26,42-52]. Others determine 
a main compound and its reduced metabolite [27,53-59], sometimes together with additional 
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metabolites [24,60-67]. One method could be applied to each of the four pairs (main 
compound and respective reduced metabolite) individually [68]. Four methods were 
developed that could determine simultaneously two or more main compounds alone [69] or 
together with their reduced metabolites [13,70-72].  
If the alpha-phase after intravenous bolus administration has to be included in the assay and 
undiluted samples are to be measured, it should be kept in mind that plasma concentrations 
for the main compounds up to 10,000 ng/mL are possible. If not, plasma concentrations are 
1000 ng/mL or lower. Lower limits of quantification (LLOQ) in the low ng/mL range (< 10 
ng/mL) should guarantee detection up to 24 hours or more after administration. For the 
reduced metabolites, a similar LLOQ and an upper limit of quantification (ULOQ) of 250 
ng/mL in plasma is advisable [6-8,73]. In addition to the determination of the LOQ (and 
LOD, limit of detection), the validation of analytical methods for the pharmacokinetic 
determination of anthracyclines in (pre)clinical studies requires that parameters such as 
precision and accuracy meet pre-set acceptance criteria and parameters such as selectivity, 
stability, linearity and recovery are evaluated [74-76]. 
 
3.2. Sample preparation  
Three major strategies are described for sample preparation, i.e. deproteinization, liquid-liquid 
extraction and solid phase extraction (SPE). A combination of these approaches has also been 
applied.  
 
3.2.1. Deproteinization  
Of the four existing protein precipitation techniques (organic solvents, metal ion, acid and 
salt) [77], only the former three have been applied.  
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Organic solvent precipitants decrease hydrophobic interactions between proteins, while 
facilitating electrostatic interactions, resulting in protein aggregation. As organic solvent, 
acetonitrile (pure or in combination with an acidic buffer or acid) [53,54,58,64], methanol 
[59,62] and ethanol [13] have been used.  
Zinc sulphate, always in the presence of methanol [24,45], acetone [26,52,55] or both [43] has 
also been applied for protein precipitation. Zinc, a positively charged metal ion, will interact 
with proteins, reducing a protein’s solubility by altering its iso-electric point and by 
displacing protons, resulting in a lowering of the solution’s pH. 
Lastly, insoluble salt formation via application of acidic reagents has been applied. Both the 
use of aqueous perchloric acid and hydrochloric acid solutions, always in the presence of a 
small amount of organic solvent, has been described [51,57]. Use of the former does not pose 
a danger as long as no heating and/or solvent evaporation is involved. 
Although protein precipitation is mostly combined with an extraction step (see following 
paragraphs), its use as a single sample pre-treatment step offers great advantages in terms of 
speed and simplicity, though, possibly at the expense of the quantification of low 
concentrations. Moreover, matrix effects should be extensively evaluated in the case of mass 
spectrometric (MS) detection [77]. In addition, when zinc sulphate precipitation is to be 
followed directly by MS detection, non-volatile salt build-up in the mass spectrometer’s 
interface should be prevented. This can be achieved by including a solvent like acetone in the 
precipitation step, preventing water and zinc sulphate to move into the supernatant, and/or by 
applying a solvent divert to waste [43,77]. Additionally, the effect of zinc sulphate has been 
reported to be dependent on the type of anticoagulant [24]. 
It is hard to list the protein precipitants of choice to be used for anthracycline analysis in 
plasma or serum. Important factors to consider are: i) the effectiveness (with e.g. zinc sulphate 
and acetonitrile being described as very effective precipitants) [77], ii) possible co-
10 
 
precipitation, iii) the limitations imposed by a subsequent additional liquid-liquid or solid 
phase extraction and iv) the detection method to be used, with (tandem) mass spectrometry 
sometimes being more prone to matrix-associated effects than e.g. fluorescence-based 
detection. 
 
3.2.2. Liquid-liquid extraction  
Two major strategies have been followed: (1) an extraction followed by an evaporation step 
[13,42,61,63] or (2) an extraction followed by a back-extraction [27,53,68]. Since the first 
step is in both cases similar, this will be discussed together.  
 
Extraction into an organic solvent (mixture)  
Ethylacetate [53], dichloromethane [13], and mixtures of chloroform with n-propanol [61,63] 
isopropanol [27,42]  or 1-heptanol [68] have been used as extractants, mostly after addition of 
a mild alkaline buffer (buffer pH-range 8.5 to 9.5) to obtain high recoveries.  
Although there is a declining trend in the use of chloroform as an extractant because of 
environmental and health issues, if it is used, attention should be paid to the stabilizer. More 
specifically, ethanol-stabilized chloroform should be preferred over non- or amylene-
stabilized chloroform because phosgene formation in these latter may impair anthracycline 
extraction and lead to artefacts [78]. Extraction under neutral or mildly alkaline conditions 
results in a partial recovery of glucuronic acid metabolites. Since the analytes are diluted by 
transfer into the organic phase, an evaporation step or back-extraction is necessary.  
 
Back-extraction into an aqueous solution  
A small volume of diluted phosphoric [27,68] or hydrochloric [53] acid has been applied to 
perform an efficient back-extraction of the organic phase. Incorporation of this step leads to 
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an improved sample clean-up, but is more time-consuming. All aglycones are almost 
completely lost during this step. As these are not considered to be toxicologically relevant, 
this is not a problem in the vast majority of cases; however, it is relevant when a complete 
metabolite profile is to be made. In addition, when LC-MS/MS is to be performed, one may 
opt to use a volatile acid for the back-extraction or to include a solvent divert to waste prior to 
entrance of the compounds in the mass spectrometer. 
 
3.2.3. Solid phase extraction 
Solid phase extraction is widely used to extract anthracyclines. Besides silica based reversed-
phase C18 [46,47,56,60,66,67,70], C8 [72] and C2 [44,65] sorbents, also polymeric Oasis 
HLB [48,49,57,71] and MCX [50] sorbents have been employed. A Biotrap 500 MS online 
SPE column has also been used [69]. 
To avoid losses due to protein binding, samples have sometimes been diluted [50,65,66,71,72] 
or have been subjected to a protein precipitation step [57] prior to loading on the sorbent. 
Mild washing conditions, usually consisting of water, a neutral or slightly acidic buffer, 
sometimes in the presence of a small percentage of organic solvent (up to 10% methanol or 
acetonitrile), have been applied [44,46-50,56,57,60,65,67,69-72]. Occasionally, a stronger 
(additional) wash-step was included: 25 or 30% methanol at neutral pH [50,56,66], 40% 
methanol at alkaline conditions [48,49] or hexane [46]. Mild washing conditions improve 
recoveries, especially if the reduced metabolites or glucuronic acid conjugates have to be 
included in the assay. 
Methanol (pure or in combination with an acid or tetrahydrofuran) [47-49,56,57,60,66,67], 
acetonitrile – acidic buffer mixtures [71,72] and chloroform – alcohol combinations [46,70] 
have been applied to elute the C18, C8 and Oasis HLB sorbents. The C2 sorbents and Biotrap 
500 MS column were eluted either online with the mobile phase [65,69] or with a 0.28 M 
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formate buffer (pH 3.55) : acetone : isopropanol (60:32:8, v/v/v) mixture [44], while the Oasis 
MCX sorbent was eluted with an alkaline methanol – acetonitrile mixture [50]. 
Solid phase extraction offers a good alternative for liquid-liquid extraction, in which all but 
one of the methods make use of halogenated solvents. No consistent differences can be seen 
between SPE and liquid-liquid extraction with respect to reported recoveries (in most cases 
around or above 80%) or sensitivities (LLOQ in the low ng/mL range) (Table 1). Mostly 
applied SPE sorbents are C18 and polymeric sorbents, both of which have proven their utility 
for the determination of both the main compounds and their metabolites. As is common in 
SPE, the choice of the stringency of the washing solvent is a compromise; given the same 
retention of the main compound, more stringent washing steps may lead to cleaner extracts, 
but with less retention of several metabolites. 
 
3.3. Chromatographic analysis 
 
3.3.1. Liquid chromatography coupled to fluorescence detection 
HPLC coupled to fluorescence detection has been the method of choice for many years. 
Reversed-phase C18 stationary phases have been widely used 
[13,24,26,27,44,45,50,51,55,56,58,60,62,64,65,67,72], but also C8 [46,52,61,63], cyano 
[66,68], phenyl [47] and phenyl-hexyl [53] stationary phases have been chosen. 
Isocratic water-acetonitrile mobile phases, containing a diluted acid [27,51,53,55,58,61,63] or 
an acidic buffer [52,56,60,64,65,67,68,72], sometimes in the presence of an additional organic 
modifier such as tetrahydrofuran [55,61,63,65] or triethylamine [27,51,56,58,64,72] have 
been employed frequently. Other isocratic mobile phases have been used occasionally [24,44-
46,62]. Gradient elution, consisting of a water-acetonitrile system containing a diluted acid 
[13,26] or an acidic buffer [47,50,66], has also been applied. The pH in the methods that have 
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been applied is typically in the range 2-4 (Table 1). The choice between isocratic and gradient 
elution primarily depends on the nature and number of anthracycline(s) (metabolites) to be 
determined and on the run-time. As most isocratic methods require only a moderate 
percentage of organic solvent, column contamination may build up over time. Acetonitrile has 
been demonstrated to achieve higher resolution for anthracyclines than alcohols, and is 
therefore the organic solvent of choice [21]. A method enabling the simultaneous 
determination of the four anthracyclines, together with their respective reduced metabolites, 
was developed by our own research group [13,79]. This approach offers the advantage that 
clinical samples of patients treated with any of these compounds can be quantified in a single 
sequence, using a single set of calibrators and QC samples. 
Various excitation and emission wavelengths have been employed to detect the 
anthracyclines. Excitation wavelengths are often between 470 and 480 nm 
[13,26,27,45,47,51,55,56,60,62-66,68], although lower [46,53,61,67,72] and higher 
[24,44,50,52,58] wavelengths have been reported. Emission wavelengths frequently vary 
between 550 and 560 nm [13,26,27,45-47,50-53,55,56,61-64,68,72], although lower [58] and 
higher [24,44,60,65-67] wavelengths have been reported. Comparison of the signal-to-noise 
levels of plasma extracts at excitation wavelengths of 233, 254 and 480 nm concluded that 
480 nm was the excitation wavelength of choice [68]. Idarubicin and its metabolites have, due 
to the absence of the methoxy group at C4, slightly different excitation and emission spectra, 
when compared with the other anthracyclines.  
Liquid chromatography coupled to fluorescence detection has two distinct advantages: the 
cost of analysis is low (as compared to tandem mass spectrometry) and the technique allows 
sensitive detection of all compounds and major metabolites. Selectivity is a double-edged 
parameter: on the one hand chances are relatively small that endogenous compounds or co-
medication interfere in the analysis, due to the high wavelengths of the fluorophore. On the 
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other hand, anthracyclines undergo a complex metabolism yielding many fluorescent 
metabolites. Great care should be taken in investigating such interferences. This can be 
problematic, since many metabolites are not or no longer commercially available. This is 
nicely exemplified by e.g. epirubicin glucuronide, for which no commercially available 
standards exist and which may be strongly retained by C18 columns, resulting in 
unexpectedly late elution, near or even later than epirubicin. Therefore, we highly recommend 
this glucuronide to be included during method optimization, either patient-derived or in vitro 
generated, utilizing insect-cell derived microsomes in which the glucuronidating enzyme 
UGT2B7 is expressed [80,81]. 
 
3.3.2. Liquid chromatography coupled to mass spectrometry 
In 2000, Lachâtre and coworkers [70] developed a pioneering method for the simultaneous 
determination of the four anthracyclines and the respective reduced metabolites of three of 
these in serum. The compounds were eluted from the C18 column with an isocratic mobile 
phase consisting of water:acetonitrile containing a 5 mM ammonium formate buffer (pH 3.0). 
Analytes were detected in a single quadrupole mass spectrometer after electrospray ionization 
with in-source fragmentation. Good sensitivity and selectivity were obtained, and the method 
is applicable over a broad concentration range.  However, nowadays there is a trend towards 
using tandem mass spectrometric detection, which has become more widely available since 
then. 
 
3.3.3. Liquid chromatography coupled to tandem mass spectrometry  
During the last years, a number of liquid chromatographic – tandem mass spectrometric (LC-
MS/MS) methods have been developed. Compounds were separated on a C18 [42,49,54,57] 
or phenyl [43] stationary phase by application of an isocratic [42,54] or gradient [43,49,57] 
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water:acetonitrile mobile phase containing 0.1% formic acid [42,43,49] or 5 mM ammonium 
acetate buffer pH 3.5 [54,57].  
Analytes are usually detected after electrospray ionization (ESI) in the positive mode 
[43,49,54,57], although also atmospheric pressure chemical ionization (APCI) [42] has been 
described. Both ionization techniques have been claimed to be preferable to the other, based 
on sensitivity criteria in preliminary infusion studies [42,54]. In our opinion other criteria, 
such as the extent of matrix effect and adduct formation, are also highly relevant in the choice 
of ionization technique, and these phenomena should be evaluated more thoroughly in future 
research. The aglycone metabolites are reported to have low ionization efficiencies with ESI 
[54].  
Sleno et al. [82] have written an excellent paper about the fragmentation of anthracyclines 
following ESI. An example of the fragmentation of doxorubicin is displayed in Fig. 2. 
Fragment ions of other anthracyclines can be predicted, mutatis mutandis, by this scheme.  
The same authors also investigated the intensity of selected reaction monitoring (SRM) 
transitions from the protonated anthracyclines to important fragments in function of the 
applied collision energy.  
Although in mass spectrometry, baseline separation of compounds of interest is sometimes 
considered as being less important, owing to its high, mass-based, selectivity, this 
presumption may lead to potential pitfalls in the identification and quantification of 
anthracyclines and their metabolites, because of: (1) the existence of epimers, (2) the “mass 
+2” metabolism and (3) the potential late elution of glucuronide conjugates.  
Doxorubicin and epirubicin, as well as their reduced metabolites doxorubicinol and 
epirubicinol, differ chemically only by the orientation of the hydroxylgroup at position 4’ in 
the daunosamine sugar (axial vs. equatorial). Both epimers break down in identical mass 
fragments under comparable conditions. Only at low collision energies can a small difference 
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in the intensity of some mass fragments occur: an initial water loss (yielding m/z 526) is more 
pronounced for epirubicin, whereas an initial cleavage of the glycosidic bond (yielding m/z 
415 and 397) is strongly dominant for doxorubicin [42,82]. Although this cross-interference is 
not expected to take place in patient samples (patients are only administered a single 
anthracycline), it is relevant when setting up MS-based methods capable of measuring both 
epi- and doxorubicin, using a single set of calibrators. 
The metabolism of the carbonyl function in the main compounds to an alcohol group in the 
reduced metabolites involves the addition of only 2 mass units. Therefore, the isotope 
distribution of the molecular ions of the main compounds overlaps about 6.7% with that of 
these metabolites. The overlap with commonly chosen SRM-transitions still accounts for 
more than 6% [35]. As a result, baseline separation between the main compounds and their 
reduced metabolites is a prerequisite for unambiguous identification and quantification of the 
latter ones. This aspect has not always been taken into account, as demonstrated by Fig. 3 in 
which the SRM transition of doxorubicinol is expected to be influenced by the one from 
doxorubicin. 
Glucuronide conjugates are known to be prone to conversion to their parent compounds in the 
source/interface of the mass spectrometer [83]. Especially when co-elution of the parent 
compound and its glucuronide may occur (as may be the case for epirubicin and its 
glucuronide) or has not been investigated, it cannot be excluded that the latter may contribute 
to the signal, thus compromising correct quantification. 
Owing to its high sensitivity and selectivity, tandem mass spectrometry has increasingly been 
applied for detecting anthracyclines in plasma during the last decade. However, its application 
may not result in a neglect of sample preparation or chromatographic separation, since 
phenomena such as matrix effects, adduct formation, isotope distribution and fragmentation 
need to be carefully evaluated and controlled. Thus, we do not consider anthracycline analysis 
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to be a very good candidate for a “dilute-and-shoot” approach, in which sample preparation is 
omitted and the sample is immediately introduced in the mass spectrometer.  In addition, 
although LC-MS/MS has become relatively widely available, its associated cost, both in terms 
of acquisition and maintenance, remains an important drawback. To our opinion, the 
application of LC-MS/MS for quantification of anthracyclines in pharmacokinetic studies 
cannot provide a cost-effective alternative for LC with fluorescence-based detection. The 
latter has proven to be sufficiently sensitive for detecting the pharmacologically active 
compounds, even when there is limited sample availability. 
 
3.3.4. Other chromatographic techniques 
Two liquid chromatographic methods coupled to UV detection at a wavelength of 254 nm 
have been described. The first one uses a HILIC-type stationary phase and an isocratic 
acetonitrile : water mobile phase containing an ammonium formate buffer pH 2.9 [48]. 
Selectivity with regard to metabolites was not demonstrated and sensitivity was poor. The 
second one uses gradient elution, but sensitivity is so poor that the anthracyclines can only be 
monitored for a few minutes after infusion [69].  
Liquid chromatography coupled to electrochemical detection [71] or chemiluminescence 
detection after a post-column photosensitization reaction [59] has been described but, 
although achieving good sensitivity, has only rarely been applied. 
 
3.3.5. Non-chromatographic techniques  
Although the focus of this review is on chromatographic techniques, it needs to be mentioned 
that also capillary electrophoresis with UV [84], amperometric [85] and laser-induced 
fluorescence detection [86-92] and other techniques [93,94] have been described. The 
majority of these methods have been reviewed elsewhere [16,17]. 
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4. Determination for assessing occupational exposure 
Although anthracyclines undergo mainly biliary excretion, urine is used as matrix for 
assessing occupational exposure because of its ease of collection. A small fraction of 
unchanged drug (5 to 20%) is recovered in urine, and metabolite concentrations are even 
expected to be lower [14,95,96].  
Based on current knowledge, it is virtually impossible to set a level of exposure that, beyond 
doubt, can cause no adverse effects [96]. Based on a German study of more than 1000 urine 
samples of hospital personnel, the highest concentrations reported for doxorubicin and 
epirubicin are 127 and 182 pg/mL, respectively [97]. Recently, much higher concentrations 
(up to 33,900 and 84,100 pg/mL for doxorubicin and epirubicin, respectively) were reported 
in a small Italian study [98]. Until now, daunorubicin and idarubicin have never been detected 
in urine of hospital personnel. In urine of 2 technicians working in a drug-manufacturing 
plant, epirubicin concentrations were determined to be 800 and 1200 pg/mL, respectively 
[99]. 
The analytical aspects of the trace analysis of doxorubicin, epirubicin, daunorubicin and 
idarubicin in urine have primarily been described by Sottani and coworkers, who developed 
and validated two tandem mass spectrometric methods with minor differences [99,100]. Since 
larger starting volumes are used, solid phase extraction is preferred. Typically, a 5-mL urine 
sample adjusted to pH 7.0 with 2 mL phosphate buffer was loaded to a previously conditioned 
silica based reversed-phase C18 sorbent (500 mg). After rinsing the cartridge with phosphate 
buffer and drying, compounds were eluted with 3 mL of a methylene chloride – isopropanol 
(50:50, v/v) or methylene chloride – isopropanol – methanol (50:35:15, v/v/v) mixture. After 
evaporation, the residue was reconstituted in the mobile phase starting conditions. The 
compounds were separated on a C8 stationary phase by applying a gradient mixture of 0.1% 
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formic acid in water and acetonitrile. Tandem mass spectrometric detection after electrospray 
ionization enabled detection limits and lower limits of quantification of 40, 40, 10 and 10 
pg/mL and 100, 100, 30 and 30 pg/mL for doxorubicin, epirubicin, daunorubicin and 
idarubicin, respectively [100]. 
Another method was developed by Pieri and coworkers [98]. A 3-mL acidified urine sample 
was loaded to a previously conditioned polymeric based reversed-phase sorbent (60 mg). 
After rinsing the cartridge with a 50-mM formic acid solution and drying, compounds were 
eluted with 2 times 3 mL of a dichloromethane – isopropanol (50:50, v/v) mixture. After 
evaporation the compounds were reconstituted in 50 mM formic acid. The compounds were 
separated on a C8 stationary phase by applying a gradient mixture of 0.1% formic acid in 
water and acetonitrile. Fluorimetric detection resulted in detection limits of 600 and 1200 
pg/mL for doxorubicin and epirubicin, respectively, which are much higher than those 
obtained by Sottani et al. The fact that at present it is not possible to put forward an exposure 
level that is certainly devoid of any adverse effects (any detectable level is considered to be a 
hazard), has as a consequence that it is also not possible to propose a required LOD or LLOQ, 
below one can assume that exposure can be considered as “safe”. Therefore, because of its 
high sensitivity/selectivity (pushing down the LOD and LLOQ), the method of choice for 
workplace testing of urine samples is undoubtedly LC-MS/MS. 
 
5. Conclusion 
A multitude of methods are available for the chromatographic separation and detection of the 
anthracyclines doxorubicin, epirubicin, idarubicin and daunorubicin in biological matrices. 
Following sample preparation utilizing (a combination of) deproteinization and liquid-liquid 
or solid phase extraction, anthracyclines (and their metabolites) are separated in the majority 
of cases utilizing C18 stationary phases. Most methods have opted for fluorescence detection, 
20 
 
which is relatively cheap and in most cases provides sufficient sensitivity. For the last few 
years, several methods with mass spectrometric detection have been developed as well. The 
method of choice -chromatographic separation and preferred detector- primarily depends on 
the number of anthracyclines (and metabolites) to be separated and on the aim of the detection 
(follow-up of patients or workplace monitoring). Whatever method is to be used, great care 
should be taken in achieving good chromatographic separation and in evaluating possible 
interferences, such as co-eluting metabolites (e.g. unexpectedly late eluting epirubicin 
glucuronide) and, when using mass spectrometric detection, matrix effects and adduct 
formation.
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Figure 1: Chemical structures and monoisotopic mass (amu) of doxorubicin, epirubicin, 
daunorubicin and idarubicin. For the 13-S-dihydrometabolites the reduced R2 
side chain has been depicted. 
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Figure 2: Fragmentation scheme for doxorubicin (Adapted from [82]). 
 
 
 
Figure 3: Combined SRM transitions of doxorubicinol (i, m/z 546 to 363), doxorubicin 
(ii, m/z 544 to 361) and daunorubicin (iii, m/z 528 to 321). (Adapted from 
[54]). 
 
 
Table 1: Chromatographic methods for clinical and pharmacokinetic studies. 
Ref. Compounds 
quantified 
ISTD Matrix 
(Species) 
(Study*) 
Extraction Stationary phase Mobile phase Run 
Time 
(min) 
Detection Calibration range (LLOQ)  
(ng/mL) 
Maudens et al 
2009 
[13] 
 
DOX 
EPI 
DAUN 
IDA 
DOXol 
EPIol 
DAUNol 
IDAol 
EPIDAUN plasma 
(human) 
(+) 
Deproteinization + LLE: 
1) 400 µL plasma + 1200 µL ethanol 
2) 1350 µL supernatant + 2.8 mL dichloromethane + 200 
µL 1 M phosphate buffer pH 8.5 
Purospher Star 
C18e 
(150 x 4.6 mm) 
5 µm particles 
gradient elution: 
solvent A: 0.1% formic acid in 
water 
solvent B: 0.1% formic acid in 
acetonitrile 
26 Fluorescence  
(480/555 nm) 
DOX: 2.5 – 2500   (2.5) 
EPI: 2.5 – 2500   (2.5) 
DAUN: 2.5 – 2500   (2.5) 
IDA: 1 – 1000   (1) 
DOXol: 2.5 – 1000   (2.5) 
EPIol: 2.5 – 1000   (2.5) 
DAUNol: 2.5 – 1000   (2.5) 
IDAol: 1 – 400   (1) 
Andersen et al 
1993 
[24] 
 
DOX 
DOXol 
DOXone 
DOXolone 
7d-DOXone 
7d-DOXolone 
none plasma 
(human) 
(+) 
Deproteinization: 
200 µL plasma + 20 µL 40% zinc sulphate + 200 µL 
methanol 
Supelcosil LC18 
(150 x 4.6 mm) 
3 µm particles 
isocratic elution: 
0.28 M formate buffer (pH 3.55) : 
acetone : isopropanol 
(72.5:25:2.5) 
20 Fluorescence  
(500/580 nm) 
DOX: 2.7 - 550 
DOXol: 2.7 - 550 
DOXone: 2 - 400 
DOXolone: 2 - 400 
7d-DOXone: 2 - 400 
7d-DOXolone: 2 - 400 
Kümmerle et 
al 
2003 
[26] 
DOX DAUN serum  
plasma 
(pig, rat) 
(+) 
Deproteinization: 
500 µL plasma + 100 µL water + 250 acetone + 50 µL 
70% zinc sulphate 
Nucleosil 100 
C18 AB 
(125 x 4 mm) 
5 µm particles 
gradient elution: 
solvent A: 0.2% 1-
heptanesulphonic acid (pH 4.0) 
solvent B: acetonitrile 
26 Fluorescence  
(480/550 nm) 
2 -1000   (2) 
Dodde et al 
2003 
[27] 
 
EPI 
EPIol 
DOX Plasma 
saliva 
(human) 
(+) 
LLE + LLE (method for plasma): 
1) 500 µL plasma + 100 µL methanol + 100 µL 0.2 M 
calcium dichloride + 500 µL 43 mM borax buffer (pH 
9.0) + 7 mL chloroform : isopropanol (6:1) 
2) organic phase + 200 µL 0.1 M phosphoric acid 
Nucleosil 100S 
C18 
(150 x 4.6 mm) 
5 µm particles 
isocratic elution: 
water : 0.1 M phosphoric acid : 
triethylamine : acetonitrile 
(70:3:0.07:27) 
15 Fluorescence  
(474/551 nm) 
EPI: 5 – 1000   (5) 
EPIol: 2 – 400   (2) 
Wall et al 
2007 
[42] 
 
EPI DAUN serum 
(human) 
(+) 
LLE: 
500 µL serum + 500 µL 200 mM ammonium formate 
buffer (pH 8.5) + 700 µL isopropanol + 1400 µL 
chloroform 
Prodigy ODS(3) 
100 Å 
(150 x 2.1 mm) 
5 µm particles 
isocratic elution: 
0.1% formic acid in water : 
acetonitrile (72:28) 
>14 APCI-MSMS: 
SRM for EPI: 544/397 
SRM for DAUN: 528/363 
2.5 – 2000   (2.5) 
Yang et al 
2007 
[43] 
 
DAUN DOXol plasma 
(rat) 
(-) 
Deproteinization: 
100 µL plasma + 20 µL methanol : water (1:1) + 50 µL 
70% zinc sulphate + 1 mL methanol : acetone (1:1) 
BetaBasic 
Phenyl 
(50 x 2.1 mm) 
3 µm particles 
gradient elution: 
solvent A: 0.1% formic acid in 
water : acetonitrile (75:25) 
solvent B: 0.1% formic acid in 
water : acetonitrile (10:90) 
3 ESI-MSMS: 
SRM for DAUN: 
528.5/321.4 
SRM for DOXol: 
546.3/363.1 
0.25 – 100   (0.25) 
Buehler et al 
1999 
[44] 
 
DOX DAUN plasma 
(human) 
(-) 
 
 
SPE (Isolute C2(EC) 10 mL 200 mg): 
Condition: 1 mL acetone : isopropanol (8:2) + 1 mL 
water + 1 mL 0.28 M formate buffer (pH 3.55) 
Load: 1 mL plasma diluted with 100 µL saline solution 
Wash: 0.28 M formate buffer (pH 3.55) 
Elution: 1 mL 0.28 M formate buffer (pH 3.55) : acetone 
: isopropanol (60:32:8) 
Prodigy ODS 
(250 x 4.6 mm) 
5 µm particles 
isocratic elution: 
0.28 M formate buffer (pH 3.55) : 
acetone : isopropanol (60:32:8) 
8 Fluorescence 
 (500/580 nm) 
1 – 100   (1) 
Alvarez-
Cedron et al 
1999 
[45] 
DOX none plasma 
(rat) 
(+) 
Deproteinization: 
150 µL plasma + 200 µL methanol : 40% zinc sulphate 
(1:1) 
Nucleosil C18 
(250 x 4 mm) 
10 µm particles 
isocratic elution: 
10 mM phophate buffer (pH 2.96) 
: methanol (35:65) 
<10 Fluorescence 
(470/555 nm) 
DOX: 5 – 75   (5) 
DOX: 50 – 600 
DOX: 500 – 5000 
Mou et al 
1997 
[46] 
 
DOX DAUN plasma 
(human) 
(+) 
SPE (Bakerbond spe octadecyl 3 mL): 
Condition: 3 mL methanol + 3 mL water : methanol (3:1) 
+ 3 mL 50 mM phosphate buffer (pH 8.5) 
Load: 500 µL plasma 
Wash: 2 mL water : methanol (9:1) + 2 mL hexane 
Elution: 3 times 1 mL chloroform : methanol (2:1) 
Spherisorb Octyl 
(150 x 4.6 mm) 
5 µm particles 
isocratic elution: 
water containing 0.08% 
phosphoric acid and 0.08% 
diethylamine : acetonitrile : 
methanol (25:60:15) 
15 Fluorescence  
(230/550 nm) 
10-2000 (6.25) 
Ref. Compounds 
quantified 
ISTD Matrix 
(Species) 
(Study*) 
Extraction Stationary phase Mobile phase Run 
Time 
(min) 
Detection Calibration range (LLOQ)  
(ng/mL) 
Cox et al 
1991 
[47] 
 
DOX DAUN plasma 
(dog) 
(+) 
SPE (C18 Sep-pak): 
Condition: 3 mL methanol + 3 mL methanol : water (1:1) 
+ 10 mL 50 mM phosphate buffer (pH 7.0) 
Load: 1 mL plasma diluted with 25 µL methanol 
Wash: 3 mL 50 mM phosphate buffer (pH 7.0) 
Elution: 3 mL methanol 
µBondapak-
phenyl 
(100 x 8 mm) 
10 µm particles 
gradient elution: 
solvent A: 100 mM formate 
buffer (pH 4.0) 
solvent B: acetonitrile 
24 Fluorescence  
(480/550 nm) 
25 - 1000 
Li et al 
2007 
[48] 
 
EPI EPIDAUN plasma 
(human) 
(-) 
SPE (Oasis HLB 1 mL 30 mg): 
Condition: 1 mL methanol + 1 mL water 
Load: 200 µL plasma diluted with 50 µL methanol:water 
(1:1) 
Wash 1: 1 mL 5% methanol 
Wash 2: 1 mL 40% methanol containing 2% ammonia 
Elution: 500 µL 0.5% formic acid in methanol 
Kromasil 
KR100-5SIL  
(250 x 4.6 mm) 
5 µm particles 
isocratic elution: 
40 mM ammonium formate 
buffer (pH 2.9) : acetonitrile 
(10:90) 
19 UV (254 nm) 50 – 2500   (50) 
Li et al 
2005 
[49] 
 
EPI EPIDAUN plasma 
(human) 
(+) 
SPE (Oasis HLB 1 mL 30 mg): 
Condition: 1 mL methanol + 1 mL water 
Load: 200 µL plasma diluted with 50 µL methanol:water 
(1:1) 
Wash 1: 1 mL 5% methanol 
Wash 2: 1 mL 40% methanol containing 2% ammonia 
Elution: 500 µL 0.5% formic acid in methanol 
AcQuity BEH 
C18  
(50 x 1 mm) 
1.7 µm particles 
gradient elution: 
solvent A: 0.1% formic acid in 
water 
solvent B: acetonitrile 
4 ESI-MSMS: 
SRM 1 for EPI: 544/130 
SRM 2 for EPI: 544/397 
SRM 1 for EPIDAUN: 
528/321 
SRM 2 for EPIDAUN: 
528/363 
0.5 – 100   (0.5) 
Krogh-
Madsen et al 
2010 
[50] 
DAUN 
etoposide 
Ara-C 
none plasma 
(human) 
(+) 
SPE (Oasis MCX 3 mL 60 mg): 
Condition: 2 mL MeOH + 2 mL 50 mM HCl 
Load: 500 µL plasma diluted with 500 µL 50mM HCl 
Wash: 1 mL 50 mM HCl + 1 mL 30% MeOH 
Elution: 2 times 1 mL NH4OH : MeOH : acetonitrile 
(10:95:95) 
Acclaim Polar 
Advantage II 
C18 
(150  x 4.6 mm) 
3 µm particles) 
gradient elution: 
Solvent A: phosphate buffer pH 
2.0 
Solvent B: acetonitrile 
15.5 Fluorescence 
(490/555 nm) 
DAUN: 15 – 1000   (15) 
Urva et al 
2009 
[51] 
 
DOX DAUN plasma 
(mouse) 
(+) 
Deproteinization: 
20 µL plasma + 2 µL 35% perchloric acid + 25 µL 
mobile phase 
Zorbax 300SB 
C18 
(250 x 4.6 mm) 
5 µm particles 
isocratic elution: 
water : acetonitrile : triethylamine 
(adjusted to pH 3 with phosphoric 
acid) (75:25:0.1) 
16 Fluorescence  
(480/560 nm) 
5 – 1000   (5) 
Al-Abd et al 
2009 
[52] 
DOX DAUN plasma 
(mouse) 
(+) 
Deproteinization: 
100 µL plasma + 250 µL acetone + 100 µL saturated zinc 
sulphate 
Luna C8 
(150 x 4.6 mm) 
5 µm particles 
isocratic elution (flow-rate 
gradient) : 
0.2% heptanesulphonic acid pH 4 
: acetonitrile (75:25) 
30 Fluorescence 
(482/550 nm) 
25 – 2000   (25) 
Gilbert et al 
2005 
[53] 
 
DOX 
DOXol 
DAUN plasma 
(parrot) 
(+) 
Deproteinization + LLE + LLE: 
1) 100 µL plasma + 200 µL acetonitrile 
2) supernatant + 2 mL ethyl acetate 
3) supernatant + 100 µL 50 mM hydrochloric acid 
solution 
Luna Phenyl 
Hexyl 
(100 x 4.6 mm) 
5 µm particles 
isocratic elution: 
10 mM phosphoric acid : 
acetonitrile (83:17) 
20 Fluorescence  
(235/550 nm) 
DOX: 20 – 400   (25) 
DOXol: 20 – 400   (25) 
Arnold et al 
2004 
[54] 
 
DOX 
DOXol 
DAUN plasma 
(rat) 
(-) 
Deproteinization: 
100 µL plasma + 400 µL 5 mM ammonium acetate 
buffer (pH 3.5) : acetonitrile (2:3) 
Zorbax Extend 
RR C18 
(50 x 4.6 mm) 
3.5 µm particles 
isocratic elution: 
5 mM ammonium acetate buffer 
(pH 3.5) : acetonitrile (60:40) 
5 ESI-MSMS: 
SRM for DOX: 544/361 
SRM for DOXol: 546/363 
SRM for DAUN: 528/321 
DOX: 0.2 – 5430   (0.2) 
DOXol: 0.5 – 5450   (0.4) 
de Bruijn et al 
1999 
[55] 
 
DOX 
DOXol 
DAUN plasma 
(human) 
(+) 
Deproteinization: 
1 mL plasma + 600 µL acetone + 100 µL 70% zinc 
sulphate 
Inertsil ODS-
80A  
(150 x 4.6 mm) 
5 µm particles 
isocratic elution: 
water : acetonitrile : 
tetrahydrofuran (adjusted to pH 
2.0 with perchloric acid) 
(76:24:0.5) 
45 Fluorescence  
(480/560 nm) 
DOX: 1 – 100   (1) 
DOXol: 0.5 – 50   (0.5) 
Ref. Compounds 
quantified 
ISTD Matrix 
(Species) 
(Study*) 
Extraction Stationary phase Mobile phase Run 
Time 
(min) 
Detection Calibration range (LLOQ)  
(ng/mL) 
Rossi et al 
1993 
[56] 
 
DOX 
DOXol 
EPI plasma 
urine 
(human) 
(+) 
SPE (Sep-pak ODS 500 mg) (method for plasma): 
Condition: 2 mL methanol + 2 mL water + 2 mL 10 mM 
phosphate buffer (pH 8.0) : methanol (3:1) 
Load: 1 mL plasma diluted with 50 µL 10mM 
phosphoric acid 
Wash: 1 mL water + 2.5 mL water : methanol (3:1) 
Elution: 2 mL 26mM methanolic phosphoric acid 
Ultrasphere ODS 
(250 x 2 mm) 
5 µm particles 
isocratic elution: 
20 mM phosphate buffer 
containing 0.05% triethylamine 
(pH 3.0) : acetonitrile (75:25) 
20 Fluorescence 
(470/550 nm) 
DOX: 0.3 – 100   (0.3) 
DOXol: 0.6 – 100   (0.6) 
Di Francesco 
et al 
2007 
[57] 
 
DOX 
DOXol 
cyclophos. 
DAUN plasma 
(human) 
(+) 
SPE (Oasis HLB 1 mL 30 mg): 
Condition: methanol + water 
Load: 1 mL of supernatant obtained after vortexing and 
centrifugation of 400 µL plasma + 80 µL methanol + 800 
µL 0.1 N hydrochloric acid solution 
Wash: 5% methanol 
Elution: 2 x 1 mL methanol 
Symmetry C18 
(30 x 2.1 mm) 
3.5 µm particles 
gradient elution: 
solvent A: 5 mM acetate buffer 
(pH 3.5) : methanol (95:5) 
solvent B: 5 mM acetate buffer 
(pH 3.5) : methanol (5: 95) 
11 ESI-MSMS: 
MRM for DOX: 544.4/321.2 
MRM for DOXol: 
546.2/363.2 
MRM for DAUN: 
528.5/321.0 
DOX: 7.2 – 984   (7.2) 
DOXol: 3.04 – 104   (3.6) 
Kuhlmann et 
al 
1999 
[58] 
 
IDA 
IDAol 
none plasma 
(rat) 
(-) 
Deproteinization: 
100 µL plasma + 100 µL acetonitrile 
Lichrospher 100 
RP-18 
(250 x 4 mm) 
5 µm particles 
isocratic elution: 
water : acetonitrile : 
tetrahydrofuran : phosphoric acid 
: triethylamine (adjusted to pH 
2.2 with hydrochloric acid) 
(624:330:40:2:4) 
10 Fluorescence 
(485/542 nm) 
IDA: 0.5 - 500 
IDAol: 0.5 - 500 
Ahmed et al 
2009 
[59] 
 
DOX 
DOXol 
none plasma 
(rat) 
(+) 
Deproteinization: 
50 µL plasma + 150 µL methanol 
Cosmosil 5C18-
AR-II 
(150 x 2 mm) 
5 µm particles 
Isocratic elution: 
50 mM imidazole-trifluoroacetic 
acid buffer (pH 6.8) : acetonitrile 
: ethanol (55:35:10) containing 20 
mM sodium dodecyl sulphate 
15 Chemiluminescence after 
post-column 
photosensitization reaction 
DOX: 1.1 – 543 
DOXol: 1.1 - 545 
De Jong et al 
1990 
[60] 
 
DAUN 
DAUNol 
DAUNone 
DAUNolone 
7d-DAUNone 
7d-
DAUNolone 
DOX plasma 
(human, 
mouse) 
(+) 
SPE (C18 Sep-pak): 
Condition: 5 mL methanol + 5 mL water + 5 mL 20 mM 
phosphate buffer (pH 4) : acetonitrile (9:1) 
Load: 1 mL plasma 
Wash: 2 mL 20 mM phosphate buffer (pH 4) : 
acetonitrile (9:1) 
Elution: 4 mL methanol : tetrahydrofuran (3:1) 
Microspher C18 
(200 x 4.6 mm) 
3 µm particles 
isocratic elution: 
20 mM phosphate buffer (pH 4.0) 
: acetonitrile (27:20) 
20 Fluorescence  
480/580 nm) 
DAUN: 0.5 - 130 
DAUNol: 0.5 - 130 
DAUNone: 0.4 - 100 
DAUNolone: 0.4 - 100 
7d-DAUNone: 0.4 - 95 
7d-DAUNolone: 0.4 - 95 
 
van Asperen 
et al 
1998 
[61] 
 
DOX 
DOXol 
7d-DOXone 
7d-DOXolone 
DAUN plasma 
urine 
(mouse) 
(+) 
LLE (plasma): 
200 µL plasma + 200 µL 6% borax buffer (pH 9.5) + 100 
µL acidified water (pH 2.05) + 1 mL chloroform : n-
propanol (4:1) 
Lichrosorb RP-8 
(100 x 3 mm) 
7 µm particles 
isocratic elution: 
water : acetonitrile : 
tetrahydrofuran (adjusted to pH 
2.05 with perchloric acid) 
(80:30:1) 
22 Fluorescence  
(460/550 nm) 
DOX: 1.2 – 1170   (1.2) 
DOXol: 1 – 990   (1) 
7d-DOXone: 1 – 955   (1) 
7d-DOXolone: 0.75 – 475 
(0.75) 
Zhou et al 
2002 
[62] 
 
DOX 
DOXol 
DOXone 
DOXolone 
DAUN serum 
(rat) 
(+) 
Deproteinization: 
50 µL serum + 150 µL methanol 
Xterra C18 
(150 x 4.6 mm) 
5 µm particles 
isocratic elution: 
50 mM phosphate buffer (pH 2.0) 
: acetonitrile : n-propanol 
(65:25:2) 
18.5 Fluorescence  
(480/560 nm) 
DOX: 10 – 2500   (10) 
DOXol: 5 – 1250   (5) 
DOXone: 5 -1250   (5) 
DOXolone: 5 -1250   (5) 
Beijnen et al 
1991 
[63] 
 
DOX 
DOXol 
DOXone 
DOXolone 
7d-DOXone 
7d-DOXolone 
DAUN plasma 
(human) 
(+) 
LLE: 
1 mL plasma + 1 mL 6% borax buffer (pH 9.3) + 300 µL 
acidified water (pH 2.0) + 5 mL chloroform : n-propanol 
(4:1) 
Lichrosorb RP8 
(125 x 4 mm) 
5 µm particles 
isocratic elution: 
water (adjusted to pH 2.2 with 
phosphoric acid) : acetonitrile : 
tetrahydrofuran (80:20:0.5) 
25 Fluorescence  
(480/560 nm) 
DOX: 1 - 1000 
DOXol: 1 - 1000 
DOXone: 1 - 100 
DOXolone: 1 - 100 
7d-DOXone: 1 - 100 
7d-DOXolone: 1 - 100 
Barker et al 
1996 
[64] 
 
EPI 
EPIol 
7d-DOXone 
7d-DOXolone 
none plasma 
serum 
(human) 
(+) 
Deproteinization: 
200 µL plasma or serum + 200 µL 100 mM 
orthophosphoric acid : acetonitrile (1:4) 
Spherisorb C18 
(250 x 4.6 mm) 
5 µm particles 
isocratic elution: 
60 mM phosphate buffer 
containing 0.05% triethylamine 
(pH 4.2) : acetonitrile (65:35) 
20 Fluorescence  
(480/560 nm) 
EPI: 5 -100 
Ref. Compounds 
quantified 
ISTD Matrix 
(Species) 
(Study*) 
Extraction Stationary phase Mobile phase Run 
Time 
(min) 
Detection Calibration range (LLOQ)  
(ng/mL) 
Dobbs et al 
1991 
[65] 
 
EPI 
EPIol 
DOXolone 
7d-DOXone 
7d-DOXolone 
EPI-glu 
EPIol-glu 
DAUN plasma 
(human) 
(+) 
SPE (C2): 
Condition: 1 mL methanol + 500 µL water + 500 µL 19 
mM phosphate buffer (pH 4.0) : acetonitrile (9:1) 
Load: 1 mL plasma diluted with 500 µL water 
Wash: 500 µL 19 mM phosphate buffer (pH 4.0) : 
acetonitrile (9:1) 
Elution: online with mobile phase 
Apex II ODS 
(100 x 5 mm) 
5 µm particles 
isocratic elution: 
19 mM phosphate buffer (pH 4.0) 
: acetonitrile (9:4) 
25 Fluorescence  
(480/580 nm) 
EPI: 1 -2000 
EPIol: 1 - 250 
DOXolone: 1 - 250 
7d-DOXone: 1 - 250 
7d-DOXolone: 1 - 250 
EPI-glu: 1 - 500 
EPIol-glu: 1 - 250 
Camaggi et al 
1992 
[66] 
 
IDA 
IDAol 
IDAone 
DAUN plasma 
(human) 
(+) 
SPE (Bond Elut C18 6 mL 1 g): 
Condition: 3 mL methanol + 3 mL 10 mM phosphate 
buffer (pH 8) : methanol (2:1) 
Load: 1 mL plasma diluted with 1 mL 10 mM phosphate 
buffer (pH 8) and 1 mL methanol 
Wash: 4 mL water : methanol (3:1) 
Elution: 3 mL 30 mM methanolic phosphoric acid 
Supelcosil LC-
CN 
(250 x 4.6 mm) 
5 µm particles 
gradient elution: 
solvent A: 10 mM dihydrogen 
phosphate : acetonitrile (78:22) 
solvent B: 10 mM dihydrogen 
phosphate + 6 mM phosphoric 
acid : acetonitrile (30:70) 
20 Fluorescence  
(470/580 nm) 
IDA: 0.3 - 300 
IDAol: 0.3 - 300 
IDAone: 0.3 - 100 
Dine et al 
1990 
[67] 
 
EPI 
EPIol 
EPI-glu 
EPIol-glu 
DAUN plasma 
(human) 
(+) 
SPE (C18 Sep-pak): 
Condition: 3 mL methanol + 3 times 3 mL 50 mM 
phosphate buffer (pH 7.0) 
Load: 1 mL plasma diluted with 50 µL water 
Wash: 2 times 3 mL 50 mM phosphate buffer (pH 7.0) 
Elution: 3 mL methanol 
Hypersil ODS 
C18 
(100 x 4.6 mm) 
5 µm particles 
isocratic elution: 
formate buffer : acetonitrile 
(65:35) 
15 Fluorescence  
(254/565 nm) 
EPI: 2.5 - 1250 
EPIol: 7.3 - 937.5 
Fogli et al 
1999 
[68] 
 
DOX 
EPI 
DAUN 
IDA 
DOXol 
EPIol 
DAUNol 
IDAol 
none plasma 
(human) 
(-) 
LLE + LLE: 
1) 500 µL plasma + 500 µL 0.2 M disodium hydrogen 
phosphate (pH 8.4) + 4 mL chloroform : 1-heptanol (9:1) 
2) organic phase + 250 µL 0.1 M phosphoric acid 
Supelcosil LC-
CN 
(250 x 4.6 mm) 
5 µm particles 
isocratic elution: 
50 mM phosphate buffer (pH 4.0) 
: acetonitrile (65:35) 
15 Fluorescence  
(480/560 nm) 
DOX: 0.4 – 10000  (0.4) 
EPI: 0.4 – 10000   (0.4) 
DAUN: 0.4 – 10000   (0.4) 
IDA: 0.4 – 10000   (0.4) 
DOXol: 0.4 – 10000   (0.4) 
EPIol: 0.4 – 10000   (0.4) 
DAUNol: 0.4 – 10000   (0.4) 
IDAol: 0.4 – 10000   (0.4) 
Bermingham 
et al 
2010 
[69] 
DOX 
EPI 
DAUN 
docetaxel 
paclitaxel 
none serum 
(human) 
(+) 
online SPE (Biotrap 500 MS) : 
Load : 100 L serum; mobile phase solvent A : B 
(85 :15) 
Wash: 30 mM ammonium formate buffer pH 6.8 : 
acetonitrile (98:2) 
Elution: gradient elution by mobile phase solvent A & B 
Zorbax XDB 
C18 
(150 x 4.6 mm) 
5 µm particles 
gradient elution: 
Solvent A: formate buffer pH 3.5 
: acetonitrile (90:10) 
Solvent B: 0.1% formic acid in 
water : acetonitrile (10:90) 
±25 UV (254 nm) 500 – 25000   (500) 
Lachâtre et al 
2000 
[70] 
 
DOX 
EPI 
DAUN 
IDA 
DOXol 
DAUNol 
IDAol 
ACLA serum 
(human) 
(+) 
SPE (Bond Elut C18 3 mL 200 mg): 
Condition: 3 mL methanol + 6 mL 50 mM disodium 
hydrogen phosphate buffer (pH 7.5) + 6 mL water 
Load: 500 µL serum diluted with 75 µL 5 mM formate 
buffer (pH 4.5) 
Wash: 6 mL water 
Elution: 1 mL chloroform : isopropanol (4:1) 
Symmetry C18 
(150 x 1 mm) 
3.5 µm particles 
isocratic elution: 
5 mM ammonium formate buffer 
(pH 3.0) : acetonitrile (70:30) 
25 ESI-MS: 
DOX: m/z 363 (397, 321) 
EPI: m/z 361 (397, 321) 
DAUN: m/z 321 (528) 
IDA: m/z 291 (333) 
DOXol: m/z 363 (399) 
DAUnol: m/z 321 (383, 530) 
IDAol: m/z 291 (500) 
ACLA: m/z 812 
DOX: 2.5 – 2000   (2.5) 
EPI: 2.5 – 2000   (2.5) 
DAUN: 5 -2000   (5) 
IDA: 5 – 2000   (5) 
DOXol: 5 – 200   (5) 
DAUNol: 2.5 – 200   (2.5) 
IDAol: 5 – 200   (5) 
Ricciarello et 
al 
1998 
[71] 
 
DOX 
EPI 
DOXol 
EPIol 
none plasma 
(human) 
(+) 
SPE (Oasis HLB): 
Condition: 1 mL mobile phase : water (1:3) 
Load: 200 µL plasma diluted with 600 µL mobile phase : 
water (1:4) 
Wash: 1 mL mobile phase : water (1:3) 
Elution: 600 µL mobile phase : acetonitrile (1:1) 
Lichrosorb RP-
18 
(200 x 4.6 mm) 
10 µm particles 
isocratic elution: 
water :  acetonitrile (71:29), 
containing 50 mM disodium 
hydrogen phosphate and 0.05% 
triethylamine (adjusted to pH 4.6 
with citric acid) 
25 Electrochemical: 
first electrode: +400 mV 
second electrode: -300 mV 
DOX: 1 – 500   (1) 
EPI: 1 – 500   (1) 
DOXol: 1 -500   (1) 
EPIol: 1 – 500   (1) 
Ref. Compounds 
quantified 
ISTD Matrix 
(Species) 
(Study*) 
Extraction Stationary phase Mobile phase Run 
Time 
(min) 
Detection Calibration range (LLOQ)  
(ng/mL) 
Nicholls et al 
1992 
[72] 
 
DOX 
EPI 
DOXol 
EPIol 
DOXone 
DOXolone 
7d-DOXone 
DAUN serum 
(horse) 
(-) 
SPE (Bond Elut C8): 
Condition: not specified 
Load: 1 mL aliquot of solution obtained after mixing 800 
µL serum with 1.2 mL 20 mM phosphate buffer (pH 4.0) 
Wash: 3 times 1 mL water + 3 times 1 mL 20 mM 
phosphate buffer (pH 4.0) 
Elution: 500 µL 200 mM disodium hydrogen phosphate 
(containing 0.05% triethylamine and adjusted to pH 3.6 
with 0.1 M citric acid) : acetonitrile (32.5:67.5) 
Spherisorb 
ODS1 
(250 x 4.6 mm) 
5 µm particles 
isocratic elution: 
60 mM disodium hydrogen 
phosphate containing 0.05% 
triethylamine (adjusted to pH 4.6 
with 30 mM citric acid) : 
acetonitrile (65:35) 
24 Fluorescence  
(254/560 nm) 
DOX: 50 - 800 
EPI: 50 - 800 
DOXol: 50 - 800 
EPIol: 50 - 800 
DOXone: 50 - 800 
DOXolone: 50 - 800 
7d-DOXone: 50 - 800 
 
Study*: (+) resp. (-) indicate whether the method has been applied on real (pre)clinical patient or animal samples. 
Abbreviations: ISTD: internal standard; LLOQ: lower limit of quantification; DOX: doxorubicin; DOXol: doxorubicinol; DOXone: doxorubicinone; DOXolone: doxorubicinolone; 7d-DOXone: 7-deoxydoxorubicinone; 7d-DOXolone: 7-
deoxydoxorubicinolone; EPI: epirubicin; EPIol: epirubicinol; EPI-glu: epirubicin glucuronide; EPIol-glu: epirubicinol glucuronide; DAUN: daunorubicin; DAUNol: daunorubicinol; DAUNone: daunorubicinone; DAUNolone: 
daunorubicinolone; 7d-DAUNone: 7-deoxydaunorubicinone; 7d-DAUNolone: 7-deoxydaunorubicinolone; IDA: idarubicin; IDAol: idarubicinol; EPIDAUN: epidaunorubicin; ACLA: aclarubicin; cyclophos.: cyclophosphamide; Ara-C: 
cytosine arabinose; LLE: liquid liquid extraction; SPE: solid phase extraction; ESI: Electro Spray Ionization; APCI: Atmospheric Pressure Chemical Ionization; MS: mass spectrometry; MSMS: tandem mass spectrometry; SRM: selected 
reaction monitoring 
